Candidiasis
Candidiasis is an infectious disease caused by various pathogenic Candida species. It commonly occurs in immunocompromised individuals and can affect local skin, mucous membranes, as well as tissues and organs throughout the body. Our company is well-equipped to address your drug and therapy development requirements in Candidiasis therapy.
Introduction to Candidiasis
Candidiasis, a fungal infection caused by Candida species, presents a significant global health concern. Invasive candidiasis, a severe form, is a leading cause of healthcare-associated bloodstream infections in the U.S., contributing to extended hospital stays and substantial healthcare costs. The incidence of candidemia in the U.S. has remained steady at about 9 cases per 100,000 people annually. Vulvovaginal candidiasis (VVC) is prevalent among women, with an estimated 138 million cases of recurrent VVC globally each year.
Drug Targets for Candidiasis
Candidiasis presents a significant challenge, but the ttherapeutic options are limited to three main classes of antifungal drugs: polyenes, echinocandins, and azoles. Each of these classes has its drawbacks, including severe side effects, a narrow antifungal spectrum, and antifungal resistance, which constrain their clinical use. Thus, identifying new antifungal targets is crucial for developing effective antifungal agents to treat candidiasis. There are several promising antifungal target proteins and their inhibitors that hold potential for treating candidiasis.
- Targets in the cell wall: Inhibiting chitin synthase; Inhibiting GPI biosynthesis; Inhibiting chitin synthase;
- Targets in the cell membrane: inhibiting sphingolipid synthesis
- Targets in vesicle trafficking
- Targets in the drug efflux system
- Targeting a core stress response protein, Hsp90
- Targeting calcineurin
- Targeting lysine deacetylase
Fig. 1 Novel antifungal targets and their inhibitors. (Lu, H., et al., 2023)Vaccine Development of Candidiasis
Vaccines are essential for preventing fatalities, hospitalizations, and the spread of diseases caused by infectious agents. As the fatality rate from drug-resistant fungal infections and the number of immunocompromised individuals continue to increase, developing and successfully implementing an effective fungal vaccine will greatly benefit humanity.
Fig. 2 A schematic diagram showing experimental Candida vaccines. (Sahu, S.R., et al., 2022)Vaccines & Monoclonal Antibodies Against C.albicans Antigens
| Targts | Vaccine/Antibody | Development Stage |
|---|---|---|
| Als3 | rAls3p-N(vaccine) | Not determined |
| NDV-3(vaccine) | Phase Ⅰ clinical trial | |
| MAbC7(antibody) | Not determined | |
| Hsp90 | r-hsp90-CA(vaccine) | Not determined |
| pD-HSP90C(vaccine) | Not determined | |
| Mycograb | Phase Ⅲ clinical trial | |
| Eno1 | Mab12D9 | Not determined |
| CaS1(antibody) | Not determined | |
| Sap2 | Pev-7(vaccine) | Phase Ⅰ clinical trial |
| hybrid phage displaying Sap2 epitope SLAQVKYTSASSI(vaccine) | Not determined | |
| Hwp1 | Hwp1 glycopeptide conjugate (vaccine) | Not determined |
| MAb2-E8(antibody) | Not determined | |
| Hyr1 | Recombinant Hyr1 protein | Not determined |
| Mdh1p | Recombinant Mdh1p protein | Not determined |
Our Services
Our company adopts a collaborative approach, partnering closely with clients to create tailored and innovative therapy strategies for Candidiasis. We offer comprehensive support throughout the entire development process, ensuring effective and customized solutions.
Platforms of Candidiasis Therapy Development
Animal Models of Candidiasis
We have extensive experience in creating and utilizing animal models that faithfully mimic the disease traits and therapeutic reactions of Candidiasis. These models enable us to evaluate the safety and effectiveness of prospective therapies with precision.
| Non-Genetically Engineering Models | ||
|---|---|---|
| We provide an array of models designed to meet specific research requirements for Candidiasis. These models allow researchers to replicate and study the intricate biological processes associated with the disease. | ||
| Optional Models |
|
|
| Optional Species | Mice, Rats, Non-human primates, Others | |
In addition, we offer a range of comprehensive animal model services that concentrate on specific signaling pathways and molecular targets.
If you are interested in our services, please contact us as soon as possible for more information.
References
- Lu, H., et al., "Candidiasis: From cutaneous to systemic, new perspectives of potential targets and therapeutic strategies." Adv Drug Deliv Rev, (2023). 199: p. 114960.
- Sahu, S.R., et al., "Vaccines against candidiasis: Status, challenges and emerging opportunity." Front Cell Infect Microbiol, (2022). 12: p. 1002406.
- Feng, Z., et al., "Promising immunotherapeutic targets for treating candidiasis." Front Cell Infect Microbiol, (2024). 14: p. 1339501.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.